Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut - Ascendis Pharma ( NASDAQ:ASND )
Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million ( 35.9 million euros ) , missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.
| Ticker |
Sentiment |
Impact |
|
ASND
|
Neutral
|
30 %
|
|
RPRX
|
Somewhat Bullish
|
40 %
|
